For NMEs, The Song Remains The Same: Specialty Markets Eye Further Growth For 2010, While Traditional Big Pharma, Primary Care NDAs Are Few

The outlook for novel drug and biologic approvals in 2010 is strikingly similar to the beginning of 2009: specialty markets continue to gain ground on new products for primary care, and specialty firms continue to gain in the ranks of sponsors while big pharma struggles to put up successful new candidates.